Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia

Neurogastroenterology and Motility

Volumn 22, Issue 6, 2010, Pages 595-599

  Suzuki, H ^a   Hibi, T ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acetylcholine; Acetylcholinesterase; Musc arinic; Prokinetics; Rome III; Symptom

Indexed keywords

ACOTIAMIDE; CHOLINESTERASE INHIBITOR; DOPAMINE 2 RECEPTOR; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; N [2 (DIISOPROPYLAMINO)ETHYL] 2 (2 HYDROXY 4,5 DIMETHOXYBENZAMIDO) 4 THIAZOLECARBOXAMIDE; PLACEBO; PROKINETIC AGENT; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; EUROPE; FEEDING BEHAVIOR; GASTROINTESTINAL MOTILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; JAPAN; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RECEPTOR AFFINITY; SHORT SURVEY; STOMACH EMPTYING; UNSPECIFIED SIDE EFFECT;

ANIMALS; BENZAMIDES; DYSPEPSIA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES;

EID: 77951954778     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2010.01486.x     Document Type: Short Survey

References (35)

1. Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders. Gastroenterology 2006 130 : 1466 1479.
2. Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol 2006 41 : 513 523. (Pubitemid 44138192)
3. Tack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001 121 : 526 535. (Pubitemid 32822566)
4. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998 115 : 1346 1352. (Pubitemid 28545984)
5. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003 98 : 783 788. (Pubitemid 36576302)
6. Stanghellini V, Tosetti C, Paternic inverted question marko A et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996 110 : 1036 1042. (Pubitemid 26113742)
7. Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol 2005 20 : 1652 1660. (Pubitemid 43961068)
8. Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: Present status and future prospects in Japan. J Gastroenterol 2007 42 : 1 15. (Pubitemid 46357245)
9. Wilmer A, Van Cutsem E, Andrioli A, Tack J, Coremans G, Janssens J. Ambulatory gastrojejunal manometry in severe motility-like dyspepsia: lack of correlation between dysmotility, symptoms, and gastric emptying. Gut 1998 42 : 235 242. (Pubitemid 28212179)
10. Suzuki H, Inadomi JM, Hibi T. Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil 2009 21 : 688 696.
11. Iwanaga Y, Kimura T, Miyashita N et al. Characterization of acetylcholinesterase-inhibition by itopride. Jpn J Pharmacol 1994 66 : 317 322.
12. Iwanaga Y, Miyashita N, Morikawa K, Mizumoto A, Kondo Y, Itoh Z. A novel water-soluble dopamine-2 antagonist with anticholinesterase activity in gastrointestinal motor activity. Comparison with domperidone and neostigmine. Gastroenterology 1990 99 : 401 408. (Pubitemid 20219096)
13. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 1993 43 : 1078 1083. (Pubitemid 23311886)
14. Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J Smooth Muscle Res 2000 36 : 69 81.
15. Ogishima M, Kaibara M, Ueki S, Kurimoto T, Taniyama K. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J Pharmacol Exp Ther 2000 294 : 33 7. (Pubitemid 30434667)
16. Kawashima K, Fujimoto K, Suzuki T, Oohata H. Direct determination of acetylcholine release by radioimmunoassay and presence of presynaptic M1 muscarinic receptors in guinea pig ileum. J Pharmacol Exp Ther 1988 244 : 1036 1039. (Pubitemid 18090125)
17. Schworer H, Kilbinger H. Enhancement of guinea-pig intestinal peristalsis by blockade of muscarinic M1-receptors. Br J Pharmacol 1988 93 : 715 720. (Pubitemid 18069077)
18. Ren J, Harty RF. Presynaptic muscarinic receptors modulate acetylcholine release from rat antral mucosal/submucosal nerves. Dig Dis Sci 1994 39 : 1099 1106. (Pubitemid 24188856)
19. Doi Y, Murasaki O, Kaibara M et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol 2004 505 : 31 5. (Pubitemid 39535673)
20. Kusunoki M, Taniyama K, Tanaka C. Dopamine regulation of [3H]acetylcholine release from guinea-pig stomach. J Pharmacol Exp Ther 1985 234 : 713 719. (Pubitemid 15240554)
21. Kilbinger H, Wessler I. Inhibition by acetylcholine of the stimulation-evoked release of [3H]acetylcholine from the guinea-pig myenteric plexus. Neuroscience 1980 5 : 1331 1340. (Pubitemid 10055717)
22. Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008 20 : 1051 1059.
23. Monnikes H, Tebbe JJ, Hildebrandt M et al. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis 2001 19 : 201 211. (Pubitemid 34045212)
24. Hanada R, Nakazato M, Murakami N et al. A role for neuromedin U in stress response. Biochem Biophys Res Commun 2001 289 : 225 228. (Pubitemid 33108818)
25. Howard AD, Wang R, Pong SS et al. Identification of receptors for neuromedin U and its role in feeding. Nature 2000 406 : 70 4. (Pubitemid 30460212)
26. Mondal MS, Date Y, Murakami N et al. Neuromedin U acts in the central nervous system to inhibit gastric acid secretion via CRH system. Am J Physiol Gastrointest Liver Physiol 2003 284 : G963 9. (Pubitemid 36597339)
27. Zhang X, Fogel R. Involvement of glutamate in gastrointestinal vago-vagal reflexes initiated by gastrointestinal distention in the rat. Auton Neurosci 2003 103 : 19 37. (Pubitemid 36057151)
28. Sivarao DV, Krowicki ZK, Hornby PJ. Role of GABAA receptors in rat hindbrain nuclei controlling gastric motor function. Neurogastroenterol Motil 1998 10 : 305 313.
29. Iwa M, Nakade Y, Pappas TN, Takahashi T. Electroacupuncture improves restraint stress-induced delay of gastric emptying via central glutaminergic pathways in conscious rats. Neurosci Lett 2006 399 : 6 10.
30. Talley NJ, Tack JF, Kowalski DL, Borton MA, Barve A. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: Efficacy in a randomized, double-blinded, placebo-controlled dose ranging trial. Gastroenterology 2008 134 : A157 8.
31. Tack JF, Talley NJ, Kowalski DL, Borton MA, Barve A. Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia. Gastroenterology 2008 134 : A143.
32. Tack J, Masclee A, Heading R et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009 21 : 272 280.
33. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010 in press.
34. Glessner MR, Heller DA. Changes in related drug class utilization after market withdrawal of cisapride. Am J Manag Care 2002 8 : 243 250.
35. Pasricha PJ. Desperately seeking serotonin. A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 2007 132 : 2287 2290.